Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2025 06:00 ET | Source: Interius BioTherapeutics

Interius BioTherapeutics to Present at Upcoming Scientific Meetings

PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today...
January 07, 2025 06:00 ET | Source: Interius BioTherapeutics

Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe

German regulatory agency, the Paul Ehrlich Institute, granted approval to expand the INVISE Phase 1 clinical trial evaluating INT2104 for the treatment of B-cell malignancies to Europe The first...
October 23, 2024 00:01 ET | Source: Interius BioTherapeutics

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety...